Trial Profile
Durability of Early Initial Combination Therapy With Exenatide/Pioglitazone/Metformin vs Conventional Therapy in New Onset Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Jan 2024
Price :
$35
*
At a glance
- Drugs Exenatide (Primary) ; Metformin (Primary) ; Pioglitazone (Primary) ; Glibenclamide; Insulin glargine
- Indications Hepatic fibrosis; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 22 Jan 2024 Status changed from active, no longer recruiting to completed.
- 25 Sep 2020 Results presented at the 56th Annual Meeting of the European Association for the Study of Diabetes
- 03 Sep 2019 Status changed from recruiting to active, no longer recruiting.